47 results on '"Stötzer O"'
Search Results
2. 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)
- Author
-
Reinisch, M., primary, Blohmer, J-U., additional, Link, T., additional, Just, M., additional, Untch, M., additional, Stötzer, O., additional, Fasching, P.A., additional, Schneeweiss, A., additional, Wimberger, P., additional, Seiler, S., additional, Huober, J., additional, Thill, M., additional, Jackisch, C., additional, Rhiem, K., additional, Solbach, C., additional, Hanusch, C., additional, Denkert, C., additional, Engels, K., additional, Nekljudova, V., additional, and Loibl, S., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) Immediately After Intensive Cytoreduction for High-Risk Myeloid Leukemias
- Author
-
Schleuning, M., Schmid, C., Stötzer, O., Ledderose, G., Kolb, H.-J., Hiddemann, Wolfgang, editor, Haferlach, Torsten, editor, Unterhalt, Michael, editor, Büchner, Thomas, editor, and Ritter, Jörg, editor
- Published
- 2003
- Full Text
- View/download PDF
4. Adoptive Immunotherapy in Chimeras — Donor Lymphocyte Transfusions for the Treatment of Acute Myeloid Leukemia
- Author
-
Kolb, H.-J., Schmid, Ch., Woiciechowsky, A., Schleuning, M., Stoetzer, O., Schoch, C., Ledderose, G., Hiddemann, Wolfgang, editor, Haferlach, Torsten, editor, Unterhalt, Michael, editor, Büchner, Thomas, editor, and Ritter, Jörg, editor
- Published
- 2003
- Full Text
- View/download PDF
5. Adoptive Immunotherapy in Chimeras
- Author
-
Kolb, H.-J., Schmid, Ch., Schleuning, M., Stoetzer, O., Chen, X., Woiciechowski, A., Roskrow, M., Weber, M., Guenther, W., Ledderose, G., Berdel, W. E., editor, Büchner, Th., editor, Kienast, J., editor, Jürgens, H., editor, Ritter, J., editor, and Vormoor, J., editor
- Published
- 2003
- Full Text
- View/download PDF
6. Involvement of ICE-Like Proteases in Gemcitabine-Induced Programmed Cell Death
- Author
-
Stoetzer, O. J., Pogrebniak, A., Heinemann, V., Gullis, U., Darsow, M., Zabel, M., Arning, M., Wilmanns, W., Nüssler, V., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor
- Published
- 1998
- Full Text
- View/download PDF
7. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)
- Author
-
Hehlmann, Rüdiger, Voskanyan, Astghik, Lauseker, Michael, Pfirrmann, Markus, Kalmanti, Lida, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Haferlach, Claudia, Schlegelberger, Brigitte, Fabarius, Alice, Seifarth, Wolfgang, Spieß, Birgit, Wuchter, Patrick, Krause, Stefan, Kolb, Hans Jochem, Neubauer, Andreas, Hossfeld, Dieter K., Nerl, Christoph, Gratwohl, Alois, Baerlocher, Gabriela M., Burchert, Andreas, Brümmendorf, Tim H., Hasford, Jörg, Hochhaus, Andreas, Saußele, Susanne, Baccarani, Michele, von Weikersthal, L. Fischer, Hahn, M., Schlimok, G., Reichert, D., Janssen, J., Martens, U., Majunke, P., Reichert, Peter, Neben, K., Korsten, S., Scholz, Ch, Oldenkott, B., Heßling, J., Kingreen, D., Sperling, C., Schelenz, C., Blau, I., Urmersbach, A., Ludwig, W., Le Coutre, P., Arnold, R., de Wit, M., Pezzutto, A., Schäfer, E., Schroers, R., Lochter, A., Behringer, D., Ko, Y., Weidenhöfer, S., Verbeek, W., Brossart, P., Trenn, G., Pommerien, W., Krauter, J., Doering, G., Munzinger, H., Diekmann, C., Hertenstein, B., Stier, S., Möller-Faßbender, F., Hänel, M., Zöller, T., Lamberti, C., Koch, B., Henzel, A., Wagner, S., Schmalenbach, A., Hoffknecht, M., Ehninger, G., Kiani, A., Illmer, T., Aul, C., Flaßhove, M., Henneke, F., Simon, M., Müller, L., Becker, H., Janz, R., Eckart, M. J., Fuchs, R., Schlegel, F., Wattad, M., Rudolph, R., Beelen, D. W., Lindemann, A., Linck, D., Wassman, Jäger, E., Al-Batran, S., Reiber, T., Waller, C. F., Hoeffkes, H., Schulz, L., Tajrobehkar, K., Mittermüller, J., Pralle, H., Runde, V., Hoyer, A., Tessen, H., Trümper, L., Schmidt, C., Sieber, M., Eschenburg, H., Depenbusch, R., Rösel, S., Lindemann, H. W., Wolf, H., Spohn, C., Moeller, R., Hossfeld, D., Zander, A., Schafhausen, P., Köster, H., Hollburg, W., Schmitz, N., Dürk, H., Hemeier, M., Grote-Metke, A., Weischer, H., Bechtel, B., Balleisen, L., Sosada, M., Ho, A., Petersen, V., Dengler, J., Bildat, S., Hahn, L., Dietzfelbinger, H., Gröschel, W., Bartholomäus, A., Freier, W., Sievers, B., Pfreundschuh, I. M., Herrmann, T., Fauser, A., Menzel, J., Kemmerling, M., Hansen, R., Link, H., Schatz, M., Bentz, M., Prümmer, O., Kneba, M., Heymanns, J., Schmitz, S., Scheid, C., Lollert, A., Neise, M., Planker, M., Stauch, M., Schröder, M., Kempf, B., Vehling-Kaiser, U., Kremers, S., Köchling, G., Hartmann, F., Neuhaus, T., Fetscher, S., Kämpfe, D., Heil, G., Uppenkamp, M., Goldmann, B., Huber, T. Fischer, Hieber, U., Plöger, C., Griesshammer, M., Lange, C., Göttler, B., Lunscken, C., Schiel, X., Scheidegger, C., Stötzer, O., Hitz, H., Schick, H., Völkl, S., Spiekermann, K., Berdel, W., Hebart, H., Ladda, E., Schmidt, P., Burkhardt, U., Hentschke, S., Falge, C., Reschke, D., Köhne, C. A., Müller-Naendrup, C., Sauer, M., Frühauf, S., Ranft, K., Dencausse, Y., Sandritter, B., Baake, G., Hofknecht, M., Dengler, R., Edinger, M., Schenk, M., Wehmeier, A., Weidelich, H. P., Pihusch, R., Stahlhut, K., Baldus, M., Matzdorff, A., Geer, T., Schanz, S., Käfer, G., Gassmann, W., Priebe-Richter, C., Demandt, M., Springer, G., Fiechtner, H., Denzlinger, C., Schleicher, J., Assman, D., Gaeckler, R., Adam, G., Waladkhani, A., Rendenbach, B., Forstbauer, H., Kanz, L., Jacki, S., Stegelmann, F., Kalhori, N., Nusch, A., Langer, W., Müller, F., Brettner, S., Uebelmesser, B., Kamp, T., Schadeck-Gressel, C., Josten, K., Klein, O., Schwerdtfeger, R., Baurmann, H., Strotkötter, H., Fett, W., Raghavachar, A., Maintz, C., Goebler, M. C., Schlag, R., Elsel, W., Wernli, M., Heim, D., Wuillemin, W., Hess, U., Gmür, J., and Mayer, J.
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
8. 29-jährige Patientin mit Pneumonie und großen abdominellen Lymphknoten
- Author
-
Kuchenbauer, F., Ngo, T., Muth, A., Stötzer, O., and Hiller, E.
- Published
- 2005
- Full Text
- View/download PDF
9. The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation
- Author
-
Pihusch, R, Holler, E, Mühlbayer, D, Göhring, P, Stötzer, O, Pihusch, M, Hiller, E, and Kolb, H-J
- Published
- 2002
- Full Text
- View/download PDF
10. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines
- Author
-
Nuessler, V, Stötzer, O, Gullis, E, Pelka-Fleischer, R, Pogrebniak, A, Gieseler, F, and Wilmanns, W
- Published
- 1999
- Full Text
- View/download PDF
11. 168MO GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status
- Author
-
Link, T., primary, Blohmer, J-U., additional, Just, M., additional, Untch, M., additional, Stötzer, O., additional, Fasching, P.A., additional, Schneeweiss, A., additional, Wimberger, P., additional, Seiler, S., additional, Huober, J., additional, Schmitt, W.D., additional, Jackisch, C., additional, Rhiem, K.E., additional, Hanusch, C., additional, Denkert, C., additional, Sinn, B.V., additional, Engels, K., additional, Nekljudova, V., additional, and Loibl, S., additional
- Published
- 2020
- Full Text
- View/download PDF
12. CLINICAL RELEVANCE OF SOLUBLE HMGB1, RAGE AND NUCLEOSOMES IN TRAUMA AND CANCER PATIENTS: A21
- Author
-
Holdenrieder, S., Roessner, J., Hoecherl, E. F., Wolf, K., Durner, J., Hofmann, W., Hallbach, J., Fersching, D., Stötzer, O. J., Lehner, J., Wittwer, C., Siegele, B., and Nagel, D.
- Published
- 2010
13. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial
- Author
-
Boeck, S., Weigang-Köhler, K., Fuchs, M., Kettner, E., Quietzsch, D., Trojan, J., Stötzer, O., Zeuzem, S., Lordick, F., Köhne, C.-H., Kröning, H., Steinmetz, T., Depenbrock, H., and Heinemann, V.
- Published
- 2007
14. Investigating Denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules – 2 × 2 factorial design (GeparX)
- Author
-
Kümmel, S, additional, Minckwitz, G, additional, Vladimirova, V, additional, Nekljudova, V, additional, Wimberger, P, additional, Denkert, C, additional, Just, M, additional, Hanusch, C, additional, Stötzer, O, additional, Huober, J, additional, Hofmann, M, additional, Jackisch, C, additional, Blohmer, JU, additional, Schneeweiss, A, additional, Untch, M, additional, and Loibl, S, additional
- Published
- 2018
- Full Text
- View/download PDF
15. BENJAMIN CONSTANT AND THE DOCTRINAIRE LIBERAL INFLUENCE IN HISPANIC AMERICA
- Author
-
Stoetzer, O. Carlos
- Published
- 1978
16. Bolivar y el Poder Moral
- Author
-
Stoetzer, O. Carlos
- Published
- 1983
17. Raices escolasticas de la constitucion norteamericana
- Author
-
Stoetzer, O. Carlos
- Published
- 1985
18. GRUNDLAGEN DES SPANISCHAMERIKANISCHEN VERFASSUNGSDENKENS: Gedanken zum Konflikt zwischen spanischer und liberaler Staatsfassung in Hispano-Amerika
- Author
-
Stoetzer, O. Carlos
- Published
- 1969
19. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
- Author
-
Haaß, Wiltrud, Kleiner, Helga, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, Morgner, A., Herbst, R., Matek, W., Lamberti, C., Zöller, T., Koch, B., Marth, T., Henzel, A., Wagner, S., Woska, E., German CML Study Group, Neumann, F., Hoffknecht, M. M., Illmer, T., Wolf, T., Ehninger, G., Kiani, A., Platzbecker, U., Aul, C., Badrakhan, C. D., Giagounidis, A., Wernli, M., Flaßhove, M., Henneke, F., Moritz, T., Simon, M., Müller, L. L., Janz, R., Eckart, M., Häcker, B., Rech, D., Mackensen, A., Bargetzi, M., Krause, S. W., Staib, P., Schlegel, F., Wätzig, K., Rudolph, R., Wattad, M., Baur, F. K., Heit, W., Beelen, D. W., Hüttmann, A., Fischer von Weikersthal, L., Novotny, J., Trenschel, R., Lindemann, A., Linck, D., Jäger, E., Al-Batran, Salah-Eddin, Ottmann, O. G., Serve, H., Reiber, T., Semsek, D., Gro, V., Waller, C., Kühnemund, A., Hoeffkes, H. G., Lambertz, H., Schulz, L., Tajrobehkar, K., Mittermüller, J., Rummel, M. J., Burchardt, A., Pralle, H., Müller, S., Runde, V., Klei, M., Westheider, J., Hoyer, A., Tessen, H. W., Hesse, A., Trümper, L., Binder, C., Schmidt, C. A., Hirt, C., Hahn, M., Sieber, M., Eschenburg, H., Wilhelm, S., Depenbusch, R., Rösel, S., Eimermacher, H., Spohn, C., Moeller, R., Schmitz, N., Nickelsen, M., Schlimok, G., Engel, E., Haatanen, T., Hollburg, W., Platz, D., Köster, H., Bokemeyer, C., Schafhausen, P., Grote-Metke, A., Bechtel, B., Hemeier, M., Reichert, D., Sosada, M., Ganser, A., Schlegelberger, B., Ho, A. D., Rohlfing, S., Dengler, J., Petersen, V., Porowski, P., Hahn, L., Dietzfelbinger, H., Weiß, Christel, Janssen, J., Gröschel, W., Bartholomäus, A., Pfreundschuh, M., Kemmerling, M., Hansen, R., Reeb, M., Link, H., Mahlmann, S., Mezger, J., Schatz, M., Furkert, J., Schmier, M., Gatter, J., Neumann, S., Heymanns, J., Steinmetz, H. T., Schmitz, S., Scheid, C., Planker, M., Frieling, T., Lollert, A., Mandel, T., Neise, M., Schröder, M., Greif, D., Kempf, B., März, W., Kremers, S., Müller, L., Hartmann, F., Heil, G., Goldmann, B., Majunke, P. J., Heinkele, P., Gregor, M., Theobald, M., Fischer, T., Thomas, S., Hensel, M., Plöger, C., Schuster, D., Brust, J., Hieber, U., Paliege, R., Hehlmann, R., Neubauer, A., Burchert, A., Graeven, U., Lange, C., Schmidt, G., Völkl, S., Schmidt, B., Hitz, H., Spiekermann, K., Reichert, P., Hiddemann, W., Haferlach, T., Haferlach, C., Schnittger, S., Stötzer, O., Scheidegger, C., Fischer, C., Berdel, W. E., Koppele, A., Hebart, H., Fuss, H., Snaga, A., Schmidt, P., Hoffmann, R., Reschke, D., Zirpel, I., Sauer, M., Lenk, G., Theilmann, L., Sandritter, B., Neben, K., Schenk, M., Dengler, R., Herr, W., Krause, S., Braun, B., Günther, E., Wacker, A., Pihusch, R., Baldus, M., Matzdorff, A., Staiger, H. J., Pollmeier, G., Grimminger, W., Geer, T., Schanz, S., Jür, C., Gassmann, W., Seitz, K., Kaesberger, J., Mück, R., Heim, D., Illerhaus, G., Denzlinger, C., Fiechtner, H., Springer, G., Hoffmann, D., Jacki, S. H., Kanz, L., Bross-Bach, U., Döhner, H., Stegelmann, F., Haferlach, Claudia, Gratwohl, A., Kalhori, N., Langer, W., Nusch, A., Wei, J., Kamp, T., Schadeck-Gressel, C., Schwerdtfeger, R., Josten, K. M., Klein, O., Fett, W., Tichelli, A., Strotkötter, H., Maintz, C., Groschek, M., Schlag, R., Elsel, W., Schüler, F., Dölken, G., Lindemann, H. W., Wolf, H. H., Schmoll, H. J., Korsten, S., Braumann, D., Hoelzer, P., Kleeberg, U., Hossfeld, D., Lange, E., Schubert, J., Weischer, H., Dürk, H. A., Kirchner, H. H., Bu, E C., Henesser, D., Sievers, B., Freier, W., Kaiser, U., Peest, D., Römer, E., Hermann, T., Fauser, A., Valverde, M. L., Menzel, J., Kemper, J., le Coutre, P., Hochhaus, A., La Rosée, P., Bentz, M., Prümmer, O., Kneba, M., Strack, U., Schoch, R., Severin, K., Stauch, M., Arnold, R., Karbach, U., Vehling-Kaiser, U., Köchling, G., Wei, U., Middeke, H., Neuhaus, T., Martin, H., Fetscher, S., Schmielau, J., Kämpfe, D., Ludwig, W. D., Uppenkamp, M., Wei, B., Thum, P., Wuillemin, W., Hofmann, W. K., Griesshammer, M., Tischler, H. J., Becker, M., Hanfstein, B., Müller, M., Ratei, R., Saußele, S., Lunscken, C., Kolb, H. J., Lutz, L., Hentrich, M., Nerl, C., Wendtner, C., Ladda, E., Gnad, M., Teutsch, C., Suna, H., Schmidt, E., Koschmieder, S., Falge, C., Wandt, H., Wilhelm, M., Köhne, C. H., Schweiger, C., Müller-Naendrup, C., Frühauf, S., Ludwig, F., Ranft, K., Dencausse, Y., Baake, G., Ritter, P. R., Kloke, O., Göttler, B., Schick, H. D., Schlegelberger, Brigitte, Urmersbach, A., Weidenhöfer, S., Weidinger, P., Wacker, D., Wehmeyer, J., Kreuser, E. D., Schlenska-Lange, A., Edinger, R., Andreesen, R., Wehmeier, A., Stahlhut, K., Blau, I., Käfer, G., Cerny, T., Hess, U., Priebe-Richter, C., Stange-Budumlu, O., Demandt, M., Freunek, G., Heidemann, E., Schleicher, J., Mergenthaler, H. G., Ihle, H., Boewer, C., Zeller, C., Laubenstein, H. P., Rendenbach, B., Clemens, M., Waladkhani, A. R., Forstbauer, H., Müller, F., Brettner, S., Raghavachar, A., Sperling, C., Kunzmann, V., Goebeler, M. E., Gmür, J., Schelenz, C., Koschuth, A., Kingreen, D., Heßling, J., Derwahl, K. M., Oldenkott, B., Müller, Martin C., Englisch, H. J., Thiel, E., Burmeister, T., Notter, M., de Wit, M., Rothaug, W., Büschel, G., Beyer, J., Dahmen, E., Hehlmann, Rüdiger, Biaggi, C., Lämmle, B., Friess, D., Baerlocher, G., Oppliger Leibundgut, E., Tobler, A., Just, M., Schäfer, E., Behringer, D., Brandt, M., Hofmann, Wolf-Karsten, Schmiegel, W., Vaupel, H. A., Verbeek, W., Ko, Y. D., Sauerbruch, T., Hahn-Ast, C., Janzen, V., Schmidt-Wolf, Ingo G. H., Trenn, G., Fabarius, Alice, van der Linde, M., Pommerien, W., Fritz, L., Krauter, J., Lordick, F., Fritsch, G., Pflüger, K. H., Diekmann, C., Kullmer, J., Doering, G., Seifarth, Wolfgang, Munzinger, H., Hertenstein, B., Peyn, A., Mayer, J., Zácková, D., Kujickova, J., Stier, S., Wejda, B., Möller-Faßbender, F., and Hänel, M.
- Subjects
Adult ,Aged, 80 and over ,Chromosome Aberrations ,Adolescent ,Fusion Proteins, bcr-abl ,Antineoplastic Agents ,Chromosome Breakage ,Middle Aged ,Clonal Evolution ,Young Adult ,hemic and lymphatic diseases ,Cell Line, Tumor ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Proteolysis ,Imatinib Mesylate ,Humans ,Blast Crisis ,Separase ,Research Article ,Aged - Abstract
PLoS ONE 10(6), e0129648 (2015). doi:10.1371/journal.pone.0129648, Published by PLoS, Lawrence, Kan.
- Published
- 2015
- Full Text
- View/download PDF
20. Dosisreduzierte Konditionierung vor allogener Stammzelltransplantation: Grundprinzipien, klinische Protokolle und erste Ergebnisse
- Author
-
Schmid, Christoph, Weisser, M., Ledderose, G., Stötzer, O., Schleuning, M., and Kolb, H.-J
- Published
- 2002
21. The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation
- Author
-
M Pihusch, Mühlbayer D, Kolb Hj, Erhard Hiller, Stötzer O, R. Pihusch, Peter Göhring, and Ernst Holler
- Subjects
Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,Adolescent ,medicine.medical_treatment ,Prednisolone ,Gastroenterology ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Antilymphocyte Serum ,Retrospective Studies ,Disseminated intravascular coagulation ,Inflammation ,Transplantation ,Chemotherapy ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hemodynamics ,Hematology ,Disseminated Intravascular Coagulation ,Middle Aged ,medicine.disease ,Haematopoiesis ,Endocrinology ,Hematologic Neoplasms ,Toxicity ,Chemoprophylaxis ,Drug Evaluation ,Female ,Kidney Diseases ,business ,Complication ,Immunosuppressive Agents ,medicine.drug - Abstract
Antithymocyte globulin (ATG) is commonly used in allogeneic haematopoietic stem cell transplantation (HSCT). Little information is available, however, as to the optimal protocol for use and the side-effects occurring if ATG is administered in high daily doses (10-30 mg/kg). We report our experience with ATG Fresenius (ATG-F) in conditioning for allogeneic HSCT. During a period of 3 days, 47 patients received doses between 10 and 30 mg/kg either over 4 h preceded by 1-1.5 mg/kg prednisolone 30 min before the start of ATG-F (protocol A) or alternatively, over 12 h with 3-4 mg/kg prednisolone being administered before and 6 h after start of ATG (protocol B). During treatment with ATG-F, the side-effects observed included inflammation, disseminated intravascular coagulation, hyperdynamic circulation and renal dysfunction. Although these complications caused substantial morbidity, they were reversible within a few days. Side-effects were significantly more severe in patients treated according to protocol A than in those treated according to protocol B. As prolonged infusion of ATG-F does not reduce T cell clearance due to the long half-life of ATG-F, and since less cytokine release during conditioning might have beneficial long-term effects, we recommend administering ATG-F over 12 h preceded by high-dose steroid treatment.
- Published
- 2001
22. Polyostotische fibröse Dysplasie der Wirbelsäule und Rippen
- Author
-
Walther, E. U., primary, Grunewald, R., additional, Stötzer, O. J., additional, and Jehn, U., additional
- Published
- 2008
- Full Text
- View/download PDF
23. Second-line therapy with pemetrexed after gemcitabine failure in patients with unresectable locally advanced or metastatic pancreatic cancer: A multicenter phase II trial
- Author
-
Boeck, S., primary, Weigang-Koehler, K., additional, Fuchs, M., additional, Kettner, E., additional, Quietzsch, D., additional, Trojan, J., additional, Stötzer, O., additional, Mueller, E., additional, Depenbrock, H., additional, and Heinemann, V., additional
- Published
- 2006
- Full Text
- View/download PDF
24. Dosisreduzierte Konditionierung vor allogener Stammzelltransplantation
- Author
-
Schmid, C, primary, Weisser, M, additional, Ledderose, G, additional, Stötzer, O, additional, Schleuning, M, additional, and Kolb, H.-J, additional
- Published
- 2002
- Full Text
- View/download PDF
25. Allogene Transplantation maligner Lymphome
- Author
-
Stötzer, O J, primary, Schleuning, M, additional, Ledderose, G, additional, Hiddemann, W, additional, and Kolb, H.-J, additional
- Published
- 2001
- Full Text
- View/download PDF
26. 240 Immunohistochemical evidence of cytoplasmic and interstitial transforming growth factor β3 (TGF β) in myeloproliferative diseases (MPD)
- Author
-
Hill, W., primary, Munker, R., additional, Stötzer, O., additional, Darsow, M., additional, Jehn, U., additional, and Wilmanns, W., additional
- Published
- 1995
- Full Text
- View/download PDF
27. Further characterisation of two different resistant human leukemia cell lines with respect to apoptosis induction
- Author
-
Stötzer, O., primary, Nüssler, V., additional, Wallner, U., additional, Pelka-Fleischer, R., additional, Darsow, M., additional, Gullis, E., additional, and Wilmanns, W., additional
- Published
- 1995
- Full Text
- View/download PDF
28. Functional P-gp expression in multiple myeloma patients at primary diagnosis relapse or progressive disease.
- Author
-
Nuessler, V., Gieseler, F., Gullis, E., Pelka-Fleischer, R., Stötzer, O., Zwierzina, H., and Wilmanns, W.
- Subjects
P-glycoprotein ,MULTIPLE myeloma ,DISEASE relapse ,MONOCLONAL antibodies ,MEDICAL function tests ,MULTIDRUG resistance - Abstract
In this study, 25 multiple myeloma (MM) patients at primary diagnosis and 18 MM patients at relapse or progressive disease (PD) were examined in order to investigate the incidence of P-glycoprotein (P-gp) expression at initial diagnosis and relapse or PD. Furthermore, P-gp expression in relation to VAD regimen response was determined. P-gp expression in the myeloma cells was determined using monoclonal antibody 4E3.16 and the rhodamine 123 functional test. The percentage of patients with P-gp overexpressi0n at primary diagnosis ranged between 0 and 41% in the literature vs 32% in our study. The percentage of P-gp positive patients at relapse or PD ranged between 29 and 59% in the literature vs 33% in this analysis. All P-gp positive patients had a functional P-gp, ie a pumping P-gp. A significant difference concerning response (50 vs 58.3%) to VAD treatment and median survival (10 vs 12.5 months) between P-gp positive and P-gp negative patients could not be determined. Six of 12 P-gp negative MM patients at relapse or PD developed after VAD therapy a relapse combined with P-gp overexpression. These results do not confirm the suggestions that P-gp overexpression influences response to VAD treatment. However, the results described in the literature and our own emphasize the need for careful accompanying research programmes aimed at detecting the complexity of chemotherapy resistance in the light of developing a risk-adapting therapy for MM patients. [ABSTRACT FROM AUTHOR]
- Published
- 1997
29. The Dynamics of Change in a Slave Society. A Sociopolitical History of the Free Coloreds of Jamaica, 1800—1865 Mavis Christine Campell
- Author
-
Stoetzer, O. Carlos
- Published
- 1977
30. Das Zeitalter der Aufklärung in der Provinz Quito Ekkehart Keeding
- Author
-
Stoetzer, O. Carlos
- Published
- 1984
- Full Text
- View/download PDF
31. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
- Author
-
Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, Stötzer O, Foerster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Kreuzeder J, Guderian G, and Fasching PA
- Subjects
- Humans, Female, Aged, Middle Aged, Aged, 80 and over, Adult, Postmenopause, Progression-Free Survival, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Breast Neoplasms metabolism, Everolimus administration & dosage, Everolimus adverse effects, Receptor, ErbB-2 metabolism, Androstadienes administration & dosage, Androstadienes therapeutic use, Androstadienes adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Receptors, Progesterone metabolism, Receptors, Estrogen metabolism, Quality of Life
- Abstract
BRAWO, a real-world study, assessed the efficacy, quality of life (QoL) and safety of EVE + EXE in postmenopausal women with HR+/HER2- advanced breast cancer (ABC) in routine clinical practice. Postmenopausal women with HR+/HER2-ABC with recurrence or progression after a NSAI were included. Primary Observation parameters included the evaluation of the effectiveness of EVE + EXE. A multivariate-analysis using Cox proportional hazard model was built to identify predictors of progression. Overall, 2100 patients were enrolled (August 2012-December 2017); 2074 were evaluable for efficacy and safety analyses. Majority of patients (60.6%) received EVE + EXE as first (28.7%) or second-line (31.9%) therapy. Visceral metastases were present in 54.1% patients. Median progression-free survival (mPFS) reported as 6.6 months (95%CI: 6.3-7.0). Multivariate-analysis in a subset of patients (n = 1837) found higher body mass index (BMI) and non-visceral metastases to be independent predictors of favorable PFS. Patients with a BMI of 20 to <25 had a mPFS of 6.0 (95%CI: 5.4-6.4) and those with a BMI ≥30 had mPFS of 8.5 (95%CI: 6.9-9.9). 41.2% patients achieved stable disease and 7.3% partial response. No major changes were observed QoL; 86.4% patients received stomatitis prophylaxis and 41.4% experienced EVE related AEs of stomatitis, mainly low grade. AEs occurred in 91.2% of patients, of which stomatitis (42.6%) and fatigue (19.8%) were most frequent. The BRAWO study provides real-world evidence of efficacy and safety of EVE + EXE in patients with HR+, HER2- ABC. A high BMI and the absence of visceral metastases were independent predictors of PFS in this cohort of patients., (© 2024 UICC.)
- Published
- 2024
- Full Text
- View/download PDF
32. The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
- Author
-
Wimberger P, Blohmer JU, Krabisch P, Link T, Just M, Sinn BV, Simon E, Solbach C, Fehm T, Denkert C, Kühn C, Rhiem K, Tesch H, Kümmel S, Petzold A, Stötzer O, Meisel C, Kuhlmann JD, Nekljudova V, and Loibl S
- Subjects
- Female, Humans, Denosumab therapeutic use, Neoadjuvant Therapy, Prognosis, Breast Neoplasms pathology, Neoplastic Cells, Circulating pathology, Triple Negative Breast Neoplasms
- Abstract
Background: Disseminated tumor cells (DTCs) in the bone marrow are observed in about 40% at primary diagnosis of breast cancer and predict poor survival. While anti-resorptive therapy with bisphosphonates was shown to eradicate minimal residue disease in the bone marrow, the effect of denosumab on DTCs, particularly in the neoadjuvant setting, is largely unknown. The recent GeparX clinical trial reported that denosumab, applied as an add-on treatment to nab-paclitaxel based neoadjuvant chemotherapy (NACT), did not improve the patient's pathologic complete response (pCR) rate. Herein, we analyzed the predictive value of DTCs for the response to NACT and interrogated whether neoadjuvant denosumab treatment may eradicate DTCs in the bone marrow., Methods: A total of 167 patients from the GeparX trial were analyzed for DTCs at baseline by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3. Initially DTC-positive patients were re-analyzed for DTCs after NACT ± denosumab., Results: At baseline, DTCs were observed in 43/167 patients (25.7%) in the total cohort, however their presence did not predict response to nab-paclitaxel based NACT (pCR rates: 37.1% in DTC-negative vs. 32.6% DTC-positive; p = 0.713). Regarding breast cancer subtypes, the presence of DTCs at baseline was numerically associated with response to NACT in TNBC patients (pCR rates: 40.0% in DTC-positive vs. 66.7% in DTC-negative patients; p = 0.16). Overall, denosumab treatment did not significantly increase the given DTC-eradication rate of NACT (NACT: 69.6% DTC-eradication vs. NACT + denosumab: 77.8% DTC-eradication; p = 0.726). In TNBC patients with pCR, a numerical but statistically non-significant increase of DTC-eradication after NACT + denosumab was observed (NACT: 75% DTC-eradication vs. NACT + denosumab: 100% DTC-eradication; p = 1.00)., Conclusion: This is the first study worldwide, demonstrating that neoadjuvant add-on denosumab over a short-term period of 24 months does not increase the DTC-eradication rate in breast cancer patients treated with NACT., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
33. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
- Author
-
Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching PA, Schneeweiss A, Wimberger P, Seiler S, Huober J, Thill M, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, and Loibl S
- Subjects
- Adult, Aged, Aged, 80 and over, Albumins, Anthracyclines, Antineoplastic Combined Chemotherapy Protocols adverse effects, Denosumab adverse effects, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy methods, Paclitaxel, Prospective Studies, Receptor, ErbB-2 analysis, Treatment Outcome, Young Adult, Breast Neoplasms pathology, Triple Negative Breast Neoplasms drug therapy
- Abstract
Importance: Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)-positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear., Objective: To determine whether adding denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy (NACT) increases the pathological complete response (pCR) rate and which nab-paclitaxel schedule is more effective in the NACT setting., Design, Setting, and Participants: The GeparX was a multicenter, prospective, open-label, phase 2b, 2 × 2 randomized clinical trial conducted by GBG and AGO-B at 38 German sites between February 2017 and March 2019. The analysis data set was locked September 4, 2020; analysis was completed November 13, 2020. Patients had unilateral or bilateral primary BC, stage cT2-cT4a-d or cT1c, with either clinically node-positive or pathologically node-positive or HR-negative disease, or Ki-67 proliferation index greater than 20%, or ERBB2 (formerly HER2)-positive BC., Interventions: Patients were randomized to receive or not receive denosumab, 120 mg subcutaneously every 4 weeks for 6 cycles, and either nab-paclitaxel, 125 mg/m2 weekly for 12 weeks or days 1 and 8 every 3 weeks for 4 cycles (8 doses), followed by 4 cycles of epirubicin/cyclophosphamide, 90/600 mg/m2 (every 2 weeks or every 3 weeks). Carboplatin was given in triple-negative BC (TNBC), and trastuzumab biosimilar ABP980 plus pertuzumab was given in ERBB2-positive BC (ERBB2-positive substudy)., Main Outcomes and Measures: The primary outcome was pCR rates between arms for each randomization., Results: A total of 780 female (n = 779) and male (n = 1) patients (median [range] age, 49.0 [22-80] years) were randomized to the 4 treatment groups. The pCR (ypT0 ypN0) rate was 41.0% (90% CI, 37%-45%) with denosumab vs 42.8% (90% CI, 39%-47%) (P = .58) without denosumab, irrespective of BC subtype. Nab-paclitaxel weekly resulted in a significantly (significance level of α = .10) higher pCR rate of 44.9% (90% CI, 41%-49%) vs 39.0% (90% CI, 35%-43%) (P = .06) with nab-paclitaxel days 1 and 8 every 3 weeks. The pCR rates for nab-paclitaxel schedules in subgroups were only significantly different for TNBC (60.4% vs 50.0%; P = .06). Grade 3 to 4 toxic effects did not differ with or without denosumab. Nonhematologic toxic effects of grade 3 to 4 were higher with nab-paclitaxel weekly (33.7% vs 24.1%; P = .004)., Conclusions and Relevance: In this randomized clinical trial, denosumab added to anthracycline/taxane-based NACT did not improve pCR rates. Nab-paclitaxel at a dosage of 125 mg/m2 weekly significantly increased the pCR rate compared with the days 1 and 8, every-3-weeks schedule overall and in TNBC, but generated higher toxicity., Trial Registration: ClinicalTrials.gov Identifier: NCT02682693.
- Published
- 2022
- Full Text
- View/download PDF
34. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
- Author
-
Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer EF, Schmitt WD, Hanusch C, Fasching PA, Lübbe K, Solbach C, Huober J, Rhiem K, Marmé F, Reimer T, Schmidt M, Sinn BV, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, and Loibl S
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms pathology, Chemotherapy, Adjuvant methods, Female, Humans, Middle Aged, Neoadjuvant Therapy methods, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Receptor, ErbB-2 genetics
- Abstract
Background: The development of anti-HER2 antibody-drug conjugates opens new therapeutic options for patients with breast cancer, including patients with low expression of HER2. To characterise this new breast cancer subtype, we have compared the clinical and molecular characteristics of HER2-low-positive and HER2-zero breast cancer, including response to neoadjuvant chemotherapy and prognosis., Methods: In this pooled analysis of individual patient data, we evaluated a cohort of 2310 patients with HER2-non-amplified primary breast cancer that were treated with neoadjuvant combination chemotherapy in four prospective neoadjuvant clinical trials (GeparSepto, NCT01583426; GeparOcto, NCT02125344; GeparX, NCT02682693; Gain-2 neoadjuvant, NCT01690702) between July 30, 2012, and March 20, 2019. Central HER2 testing was done prospectively before random assignment of participants in all trials. HER2-low-positive status was defined as immunohistochemistry (IHC) 1+ or IHC2+/in-situ hybridisation negative and HER2-zero was defined as IHC0, based on the American Society of Clinical Oncology/College of American Pathologists guidelines. Disease-free survival and overall survival data were available for 1694 patients (from all trials except GeparX) with a median follow-up of 46·6 months (IQR 35·0-52·3). Bivariable and multivariable logistic regression models and Cox-proportional hazards models were performed based on a predefined statistical analysis plan for analysis of the endpoints pathological complete response, disease-free survival, and overall survival., Findings: A total of 1098 (47·5%) of 2310 tumours were HER2-low-positive and 1212 (52·5%) were HER2-zero. 703 (64·0%) of 1098 patients with HER2-low-positive tumours were hormone receptor positive, compared with 445 (36·7%) of 1212 patients with HER2-zero tumours (p<0.0001). HER2-low-positive tumours had a significantly lower pathological complete response rate than HER2-zero tumours (321 [29·2%] of 1098 vs 473 [39·0%] of 1212, p=0·0002). Pathological complete response was also significantly lower in HER2-low-positive tumours versus HER2-zero tumours in the hormone receptor-positive subgroup (123 [17·5%] of 703 vs 105 [23·6%] of 445, p=0·024), but not in the hormone receptor-negative subgroup (198 [50·1%] of 395 vs 368 [48·0%] of 767, p=0·21). Patients with HER2-low-positive tumours had significantly longer survival than did patients with HER2-zero tumours (3-year disease-free survival: 83·4% [95% CI 80·5-85·9] vs 76·1% [72·9-79·0]; stratified log-rank test p=0·0084; 3-year overall survival: 91·6% [84·9-93·4] vs 85·8% [83·0-88·1]; stratified log-rank test p=0·0016). Survival differences were also seen in patients with hormone receptor-negative tumours (3-year disease-free survival: 84·5% [95% CI 79·5-88·3] vs 74·4% [70·2-78.0]; stratified log-rank test p=0·0076; 3-year overall survival: 90·2% [86·0-93·2] vs 84·3% [80·7-87·3], stratified log-rank test p=0·016), but not in patients with hormone receptor-positive tumours (3-year disease-free survival 82·8% [79·1-85·9] vs 79·3% [73·9-83·7]; stratified log-rank test p=0·39; 3-year overall survival 92·3% [89·6-94·4] vs 88·4% [83·8-91·8]; stratified log-rank test p=0·13)., Interpretation: Our results show that HER2-low-positive tumours can be identified as new subgroup of breast cancer by standardised IHC, distinct from HER2-zero tumours. HER2-low-positive tumours have a specific biology and show differences in response to therapy and prognosis, which is particularly relevant in therapy-resistant, hormone receptor-negative tumours. Our results provide a basis for a better understanding of the biology of breast cancer subtypes and the refinement of future diagnostic and therapeutic strategies., Funding: German Cancer Aid (Deutsche Krebshilfe)., Competing Interests: Declaration of interests CD reports grants from European Commission H2020, German Cancer Aid Translational Oncology, German Breast Group, during the conduct of the study; personal fees from Novartis, Roche, MSD Oncology, Daiichi Sankyo, AstraZeneca, Molecular Health, and Merck, and grants from Myriad, outside the submitted work. CD is the cofounder of Sividon diagnostics. CD has a patent VMScope digital pathology software with royalties paid, a patent WO2020109570A1-cancer immunotherapy pending, and a patent WO2015114146A1 and WO2010076322A1-therapy response issued. AS reports grants from Celgene, Roche, and AbbVie; personal fees from Roche, AstraZeneca, Celgene, Novartis, MSD, Tesaro, Lilly, and Roche, outside the submitted work. TL receives payment or honoraria from Tesaro, MSD, Roche, Novartis, Pfizer, Amgen, Clovis, and Lilly; receives support for travel costs from Roche, Pfizer, MSD, Celgene, and Clovis; reports participation on an Advisory Board from Roche, Tesaro, Amgen, MSD, Pfizer, Lilly, Myriad, Esai, and GSK, outside the submitted work. J-UB reports personal fees from AstraZeneca, Exact Sciences, Amgen, MSD Oncology, Lilly, Novartis, Sysmex, Roche, and Sonoscape, outside the submitted work. PW reports personal fees from Amgen, AstraZeneca, MSD, Novartis, Pfizer, PharmaMar, Roche, Teva, Eisai, Clovis, and Tesaro, outside the submitted work. HT reports consulting fees and travel costs from Pierre Fabre, Pfizer Pharma, Mundipharma, ClinSol, Novartis, Lilly, Grünenthal, Vifor, AstraZeneca, Mylan, and AMGEN; payment or honoraria from Vifor, Novartis, AstraZeneca, ClinSol, Mundipharma, Lilly, and Amgen; participation on an Advisory Board from Novartis, Bristol Myers Squibb, AstraZeneca, Molecular Health, Pfizer, Roche, Grünenthal, and Mylan; and is part of a leadership or fiduciary role in Arbeitskreis klinische Studien. ASCO, BNHO, DGHO, DKG, ESMO, Deutsche Gesellschaft für Senelogie. CJ receives payment or honoraria from Roche, AstraZeneca, Novartis, Lilly, Exact Sciences, and Pierre Fabre; recieves support for travel costs from Roche and AstraZeneca, reports participation on an Advisory Board from Roche, Lilly, and AstraZeneca. MR reports consulting fees from Roche, Novartis, Lilly, and Somatex; receives payment or honoraria from Novartis, Roche, Lilly, Somatex, and AstraZeneca; recieves support for travel costs from Novartis, Pfizer, and Celgene. EFS receives payment or honoraria from AstraZeneca, Pfizer, Celgene, Roche, and Amgen; support for travel costs from Amgen, AstraZeneca, Celgene, Clovis Oncology, Eisai, Erbe, Gedeon, Richter, Genomic Health, Jenapharm, Johnson Johnson, KLS Martin, Matramed, Medac, Mentor, Novartis, Pfizer, Pharma Mar, MSD, Roche, Samsung, Storz, Tewa, Vifor, Medconcept, and Thieme; is part of a leadership or fiduciary role of University of Saarland, Germany, society for German Gynecological Endoscopy. CH reports personal fees from Pfizer, Roche, Novartis, Lilly, AstraZeneca, Celgene, outside the submitted work. PAF reports personal fees from Novartis, Pfizer, Daiichi-Sankyo, AstraZeneca, Eisai, Merck Sharp & Dohme, Lilly, Pierre Fabre, Seattle Genetics, Roche, and Hexal, and grants from Biontech and Cepheid, during the conduct of the study. KL receives payment from Roche, Pfizer, MSD, Novartis, Lilly, and Genomic Health, support for travel costs from Roche, and reports participation on an Advisory Board from Roche, MSD, and Esai. JH reports research grants to institution from Celgene, Novartis, and Hexal; consulting fees from Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, MSD, Celgene, and Abbvie; receives payment from Lilly, Novartis, Roche, Pfizer, AstraZeneca, MSD, Celgene, Eisai, and Abbvie; recieves support for travel costs from Roche, Pfizer, Novartis, Celgene, and Daiichi. TR reports consulting fees from Pfizer, honoraria for presentations from AstraZeneca and receives payment from Pfizer, Roche, and Novartis. MS reports grants from AstraZeneca, BioNtech, Eisai, German Breast Group, Genentech, Novartis, Pantarhei Bioscience, Pfizer, Pierre Fabre, and Roche; consulting fees from AstraZeneca, Eisai, Lilly, Novartis, Pantarhei Bioscience, Pfizer, Pierre Fabre, Roche, and SeaGen; receives payment or honoraria from AstraZeneca, Novartis, Pfizer, Roche, and SeaGen; support for travel costs from Pfizer and Roche; has planned patents, issued or pending from EP 2951317 B1 and EP 2390370 B1; reports participation on an Advisory Board from AstraZeneca, Eisai, Lilly, Novartis, Pantarhei Bioscience, Pfizer, Pierre Fabre, Roche, and SeaGen; medical writing support from Roche. WJ reports grants and personal fees from Sanofi-Aventis, Novartis, Lilly, Pfizer, Roche, Chugai, AstraZeneca, MSD, and Daiichi Sankyo, during the conduct of the study. ES reports consulting fees from Roche and AstraZeneca; receives payment or honoraria from Roche, Pfizer, Novartis, and Astra Zeneca; support for travel costs from Roche, Pfizer, and Daiko. SSe reports reimbursement of travel costs from Novartis and personal fees from Roche, Mundipharma, and Amgen, outside the submitted work. MU reports personal fees and non-financial support from Abbvie, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Lilly Int, MSD Merck, Mundipharma, Myriad Genetics, Odonate, Pfizer, Roche Pharma, Sanofi Aventis Deutschland, TEVA Pharmaceuticals, Novartis, and Clovis Oncology; personal fees from Bristol Myers Squibb, Lilly Deutschland, PUMA Biotechnology, Pierre Fabre, Seattle Genetics, outside the submitted work. SL reports grants or fundings from Amgen, AstraZeneca, Celgene, Novartis, Immunomedics, Pfizer, Roche, DSI Trevor, Vifor, Abbvie, Cepheid, Seagen, and VM Scope; receives payment or honoraria from AstraZeneca, Roche, Novartis, Pfizer, Prime/Medscape, Puma, and Samsung; has planned patents, issued or pending from EP14153692.0; reports participation on an Advisory Board from Amgen, AstraZeneca, DSI, Roche, Merck, Pfizer, BMS, SeaGen, Eirgenix, Celgene, Abbvie, Lilly, GlaxoSmithKline, and Pierre Fabre; is part of a leadership or fiduciary role from BIG. All other authors report no conflicts of interests., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
35. Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study.
- Author
-
Höllein A, Bojko P, Schulz S, Neitz J, Stötzer O, Pihusch R, Abedinpour F, Schmidt B, and Hentrich M
- Subjects
- Adult, Aged, Aged, 80 and over, COVID-19 diagnosis, COVID-19 therapy, Cohort Studies, Female, Germany epidemiology, Hospitalization, Humans, Incidence, Male, Middle Aged, Neoplasms therapy, Prognosis, SARS-CoV-2 isolation & purification, Severity of Illness Index, COVID-19 epidemiology, COVID-19 pathology, Neoplasms epidemiology
- Published
- 2021
- Full Text
- View/download PDF
36. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
- Author
-
Potthoff K, Stötzer O, Söling U, Hansen R, Harde J, Dille S, Nusch A, and Marschner N
- Subjects
- Adult, Aged, Aged, 80 and over, Albumins adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Biomarkers, Tumor metabolism, Breast pathology, Breast surgery, Breast Neoplasms diagnosis, Breast Neoplasms mortality, Breast Neoplasms pathology, Chemotherapy, Adjuvant adverse effects, Chemotherapy, Adjuvant methods, Disease-Free Survival, Female, Humans, Mastectomy, Middle Aged, Neoplasm Staging, Paclitaxel adverse effects, Peripheral Nervous System Diseases chemically induced, Progression-Free Survival, Prospective Studies, Quality of Life, Receptor, ErbB-2 analysis, Receptors, Estrogen analysis, Receptors, Estrogen metabolism, Receptors, Progesterone analysis, Receptors, Progesterone metabolism, Albumins administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Biomarkers, Tumor analysis, Breast Neoplasms therapy, Paclitaxel administration & dosage, Peripheral Nervous System Diseases epidemiology
- Abstract
Background: There are only scarce data on treatment of elderly patients with nab-paclitaxel for metastatic breast cancer, especially from the real-world setting. Here we present data from the noninterventional study NABUCCO with special focus on taxane-induced peripheral neuropathy (TIPN) in younger and elderly patients., Patients and Methods: A total of 407 patients with HR-positive/HER2-negative metastatic breast cancer were enrolled between April 2012 and April 2015 into the prospective, multicenter, noninterventional study NABUCCO. Details on effectiveness, tolerability, and safety of nab-paclitaxel were evaluated for younger (<70 years) and elderly (≥70 years) patients., Results: Neither median time to progression (TTP, younger 6.0 months, 95% confidence interval [CI], 5.5-7.1; elderly 6.9 months, 95% CI, 5.5-8.6) nor median overall survival (younger 16.4 months, 95% CI, 14.2-18.1; elderly 14.5 months, 95% CI, 11.9-17.4) differed by age group, also not in view of prior treatments. A multivariate regression model revealed that age did not significantly influence the TTP. TIPN was reported by 49.0% younger (44.3% common terminology criteria for adverse events [CTCAE] grade 1/2, 4.7% grade 3/4) and 45.8% elderly patients (41.1% CTCAE grade 1/2, 4.7% grade 3/4). The cumulative nab-paclitaxel dose did not correlate with the severity/grading of TIPN., Conclusion: Treatment with nab-paclitaxel in first- or further-line of metastatic HR-positive/HER2-negative breast cancer resulted in similar effectiveness and safety, irrespective of age. Therefore, nab-paclitaxel is a valid treatment option for elderly and partially heavily pretreated patients. However, incidence of TIPN is high, influencing the patients' quality of life. A close monitoring and awareness for early TIPN symptoms is warranted., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
37. Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma - a case report.
- Author
-
Issels RD, Lindner LH, von Bergwelt-Baildon M, Lang P, Rischpler C, Diem H, Mosetter B, Eckl J, Schendel DJ, Salat C, Stötzer O, Burdach S, von Luettichau-Teichert I, Handgretinger R, Neumann J, Kirchner T, Steiger K, Boxberg M, Mansmann U, Multhoff G, and Noessner E
- Subjects
- Adolescent, Female, Humans, Hyperthermia, Induced methods, Rhabdomyosarcoma drug therapy, Rhabdomyosarcoma radiotherapy
- Abstract
Introduction: An abscopal effect is a clinical observation whereby a local treatment is associated with regression of metastatic cancer at a site distant from the primary location of treatment. Here, we describe the clinical systemic effect induced by regional hyperthermia combined with low-dose chemotherapy and provide immunologic correlates. Case presentation: A 15-year-old patient had been diagnosed with alveolar rhabdomyosarcoma (ARMS). All previous treatment options failed in the patient including haploidentical stem cell transplantation and donor lymphocyte infusion. The patient presented with local and metastatic disease, and upon admission, underwent regional hyperthermia combined with low-dose chemotherapy. Immediately following therapy severe skin reactions were observed. Skin biopsies revealed an intraepithelial lymphocytic infiltration dominated by CD3
+ /CD8+ T cells with a regular network of dendritic cells. Clinical images compared before and during sequential treatment cycles showed complete metabolic response of the local tumor for more than 10 months of therapy. In addition, metastases completely regressed although they were not direct targets of regional hyperthermia. The systemic effect was associated with enhanced frequency of NK cells and T cells expressing the lectin-like natural-killer group 2 D activating receptor (NKG2D), an increase of the CD56bright subset of NK cells, as well as an increase of effector/memory and effector CD8+ and CD4+ T cells in the blood while the percentage of CD25+ FOXP3+ regulatory T cells declined. Conclusions: Regional hyperthermia combined with low-dose chemotherapy had the potential to create a systemic effect which was associated with activation of NK cells and T cells.- Published
- 2020
- Full Text
- View/download PDF
38. Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.
- Author
-
Fruehauf S, Otremba B, Stötzer O, and Rudolph C
- Subjects
- Aged, Cytotoxins, Female, Hematologic Agents administration & dosage, Hematologic Agents adverse effects, Humans, Longitudinal Studies, Male, Middle Aged, Pre-Exposure Prophylaxis methods, Prospective Studies, Secondary Prevention methods, Treatment Outcome, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Biosimilar Pharmaceuticals administration & dosage, Biosimilar Pharmaceuticals adverse effects, Febrile Neutropenia chemically induced, Febrile Neutropenia diagnosis, Febrile Neutropenia prevention & control, Filgrastim administration & dosage, Filgrastim adverse effects, Neoplasms drug therapy
- Abstract
Introduction: Febrile neutropenia (FN) is a serious and frequent complication of cytotoxic chemotherapy. Biosimilar filgrastim (Nivestim™, Hospira Inc, A Pfizer Company, Lake Forest, IL, USA) is a granulocyte-colony stimulating factor licensed for the treatment of neutropenia and FN induced by myelosuppressive chemotherapy. The primary goal of this VENICE study (ClinicalTrials.gov identifier, NCT01627990) was to observe the tolerability, safety and efficacy of biosimilar filgrastim in patients receiving cancer chemotherapy., Methods: This was a prospective, multicenter, non-interventional, longitudinal study. Consenting adult patients with solid tumors or hematologic malignancies for whom cytotoxic chemotherapy and treatment with biosimilar filgrastim was planned were enrolled., Results: Among the enrolled patients (N = 386), 81% were female, with a median age (range) of 61 (22-92) years, with 39% >65 years old. Most patients (n = 338; 88%) had solid tumors and the remainder (n = 49; 13%) had hematological malignancies. The majority of the patients (64%) received biosimilar filgrastim as primary prophylaxis and 36% as secondary prophylaxis. At the follow-up visits, for the majority of patients (95.6%) there had been no change in chemotherapy dose due to FN. For two patients (0.5%) the chemotherapy was discontinued due to FN and for four patients (1.0%) the chemotherapy dose was reduced due to FN. For the majority of patients (96.9%) the chemotherapy cycle following the first biosimilar filgrastim treatment was not delayed due to FN. For 3 patients (0.8%), the chemotherapy was delayed following the first biosimilar filgrastim treatment. Less than one-third (29.8%) of the patients experienced ≥1 adverse event that was at least potentially related to biosimilar filgrastim treatment., Conclusions: Biosimilar filgrastim was effective and well-tolerated in both the primary and secondary prophylactic setting in patients undergoing chemotherapy for solid tumors and hematological malignancies., Trial Registration: ClinicalTrials.gov identifier, NCT01627990., Funding: Hospira Inc, A Pfizer Company, Lake Forest, IL, USA.
- Published
- 2016
- Full Text
- View/download PDF
39. [Dose-reduced conditioning before allogeneic stem cell transplantation: principles, clinical protocols and preliminary results].
- Author
-
Schmid C, Weisser M, Ledderose G, Stötzer O, Schleuning M, and Kolb HJ
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Combined Modality Therapy, Cyclophosphamide adverse effects, Dose-Response Relationship, Drug, Female, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Multiple Myeloma mortality, Radiotherapy Dosage, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclophosphamide administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Leukemia, Myeloid, Acute therapy, Multiple Myeloma therapy, Stem Cell Transplantation, Transplantation Conditioning methods, Whole-Body Irradiation methods
- Abstract
Background and Objective: In the treatment of leukemia by stem cell transplantation, the immunological effects of allogeneic T-lymphocytes presumably play a greater part than high-dosage total-body irradiation (TBI) and chemotherapy. Using this immunological effect, attempts are currently being made to reduce the dosage of pre-treatment that is toxic to stem cell, such as TBI, thereby making transplantation available for a larger group of patients at high risk for transplantation. This study presents preliminary results of three current studies of this approach., Patients and Methods: Elderly patients with chronic myeloid leukemia (CML) have an increased transplantation risk. They were conditioned with TBI that was reduced stepwise (n = 27). Patients with advanced and refractory myeloid leukemia were treated with chemotherapy and dose-reduced TBI (FLAMSA protocol; n = 54). In patients with multiple myeloma, autologous transplantation with high-dose chemotherapy preceded allogeneic transplantation possible after dose-reduced conditioning (Tandem protocol; n = 6)., Results: All three protocols of TBI gave results that were not worse than those of previous studies. Relapse ocurred not more frequently in patients with CML. In patients with high-risk AML the FLAMSA protocol gave better results. Autologous-allogeneic tandem transplantation was well tolerated and led to a good response in all patients., Conclusion: Allogeneic transplantation after dose-reduced conditioning opens up new possibilities with respect to widening indications for transplantation and improving results in hematological diseases with previously unsatisfactory treatment.
- Published
- 2002
- Full Text
- View/download PDF
40. [Allogeneic transplantation in malignant lymphoma].
- Author
-
Stötzer OJ, Schleuning M, Ledderose G, Hiddemann W, and Kolb HJ
- Subjects
- Adolescent, Adult, Disease-Free Survival, Female, Graft vs Host Disease, Hodgkin Disease mortality, Hodgkin Disease therapy, Humans, Immunotherapy, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Lymphoma mortality, Lymphoma, Follicular mortality, Lymphoma, Follicular therapy, Lymphoma, Mantle-Cell mortality, Lymphoma, Mantle-Cell therapy, Lymphoma, Non-Hodgkin mortality, Lymphoma, Non-Hodgkin therapy, Male, Middle Aged, Retrospective Studies, Risk Factors, Survival Analysis, Transplantation, Homologous, Treatment Outcome, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation, Lymphoma therapy
- Abstract
Introduction: Allogeneic transplantation of bone marrow and peripheral blood stem cells is a frequently discussed therapeutic option in the treatment of malignant lymphoma. By analysing the results of our own transplant program in patients with advanced lymphoma we tried to evaluate indications for allogeneic transplantations., Methods: Data from lymphoma patients treated at the Klinikum Grosshadern between 1985 and 2001 were analysed retrospectively., Results: 56 patients were included. 24 patients had low grade Non-Hogdkin's lymphoma (NHL) (follicular lymphoma: n = 8, mantle cell lymphoma: n = 6) or chronic lymphocytic leukemia (CLL: n = 10), 16 patients had high grade NHL (immunoblastic/lymphoblastic: n = 5; large cell/diffuse: n = 5) and 8 patients suffered from Hodgkins's disease. Median age was 41 years, 34 patients were transplanted from an HLA-identical sibling, 19 from an HLA-id. unrelated donor and three from an HLA-mismatched related donor. 30 patients received bone marrow and 26 peripheral blood stem cells. 22 pat. were treated with an intensive 12 Gy TBI containing conditioning regimen, whereas 34 patients were treated with a dose-intensity reduced conditioning procedere. 25 patients are alive between 2 month and 15 years after transplantation. Overall survival after 2 years is 48 % for patients with low grade NHL (incl. CLL), 9.3 % for patients with high grade lymphoma and 25 % for patients with Hodgkin's disease. 1-year-transplant-related mortality (TRM) was 33.9 % in all patients. Dose-intensity-reduced conditioning was not able to reduce TRM., Conclusions: Allogeneic bone marrow or stem cell transplantation is able to induce long lasting complete remissions in patients with heavily pretreated malignant lymphoma. Results of allogeneic transplantation are encouraging in patients with follicular and other low grade lymphoma. However transplant-related toxicity is high. At present the impact of reducing the intensity of conditioning is not yet clear.
- Published
- 2001
- Full Text
- View/download PDF
41. In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.
- Author
-
Nüssler V, Pelka-Fleisc R, Gieseler F, Hasmann M, Löser R, Gullis E, Stötzer O, Zwierzina H, and Wilmanns W
- Subjects
- ATP-Binding Cassette Transporters analysis, Antibodies, Monoclonal immunology, Cell Division drug effects, Drug Screening Assays, Antitumor, Humans, Multidrug Resistance-Associated Proteins, Tumor Cells, Cultured drug effects, Vault Ribonucleoprotein Particles, ATP Binding Cassette Transporter, Subfamily B, Member 1 antagonists & inhibitors, Cyclosporins pharmacology, Dihydropyridines pharmacology, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Leukemia, T-Cell pathology, Neoplasm Proteins antagonists & inhibitors, Tamoxifen analogs & derivatives, Tamoxifen pharmacology, Verapamil pharmacology
- Abstract
P-glycoprotein(P-gp)- related resistance is one of the major obstacles in treating leukemia patients. Therefore, it is of clinical interest to find new potential modulators and compare their P-gp-modulating efficacy. The present analysis investigated the influence of P-gp modulators, such as verapamil, tamoxifen, droloxifene E, droloxifene Z, SDZ PSC 833 (PSC 833) and dexniguldipine in a leukemic T-cell line (CCRF-CEM) and its P-gp-resistant counterparts (CCRF-CEM/ACT400 and CCRF-CEM/VCR1000). P-gp expression was assessed with an immunocytological technique using the monoclonal antibody 4E3.16. It was characterized as the percentage of P-gp positive cells and also expressed as a D value by using the Kolmogorov Smirnov statistic. The efficacy of P-gp modulators was determined with the rhodamine-123 accumulation test and the MTT test. An in vitro modulator concentration between 0.1 microM and 3 microM was determined, where no genuine antiproliferative effect was apparent. The modulators PSC 833 and dexniguldipine were the significant (p
- Published
- 1998
- Full Text
- View/download PDF
42. Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease.
- Author
-
Nuessler V, Gieseler F, Gullis E, Pelka-Fleischer R, Stötzer O, Zwierzina H, and Wilmanns W
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 analysis, Adult, Aged, Antibodies, Monoclonal, Bence Jones Protein analysis, C-Reactive Protein analysis, Cytarabine administration & dosage, Dexamethasone administration & dosage, Disease Progression, Disease-Free Survival, Humans, Immunoglobulin G blood, Immunoglobulin M blood, Middle Aged, Multiple Myeloma blood, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Neoplasm Staging, Prognosis, Recurrence, Survival Rate, Vincristine administration & dosage, beta 2-Microglobulin analysis, ATP Binding Cassette Transporter, Subfamily B, Member 1 biosynthesis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Multiple Myeloma pathology
- Abstract
In this study, 25 multiple myeloma (MM) patients at primary diagnosis and 18 MM patients at relapse or progressive disease (PD) were examined in order to investigate the incidence of P-glycoprotein (P-gp) expression at initial diagnosis and relapse or PD. Furthermore, P-gp expression in relation to VAD regimen response was determined. P-gp expression in the myeloma cells was determined using monoclonal antibody 4E3.16 and the rhodamine 123 functional test. The percentage of patients with P-gp overexpression at primary diagnosis ranged between 0 and 41% in the literature vs 32% in our study. The percentage of P-gp positive patients at relapse or PD ranged between 29 and 59% in the literature vs 33% in this analysis. All P-gp positive patients had a functional P-gp, ie a pumping P-gp. A significant difference concerning response (50 vs 58.3%) to VAD treatment and median survival (10 vs 12.5 months) between P-gp positive and P-gp negative patients could not be determined. Six of 12 P-gp negative MM patients at relapse or PD developed after VAD therapy a relapse combined with P-gp overexpression. These results do not confirm the suggestions that P-gp overexpression influences response to VAD treatment. However, the results described in the literature and our own emphasize the need for careful accompanying research programmes aimed at detecting the complexity of chemotherapy resistance in the light of developing a risk-adapting therapy for MM patients.
- Published
- 1997
43. Autoantibodies against p53 are not increased in human ascites and pleural effusions.
- Author
-
Munker R, Stötzer O, Darsow M, Classen S, Lebeau A, and Wilmanns W
- Subjects
- Antibody Specificity, Enzyme-Linked Immunosorbent Assay, Humans, Antigens, Neoplasm analysis, Ascites immunology, Autoantibodies analysis, Pleural Effusion, Malignant chemistry, Tumor Suppressor Protein p53 immunology
- Abstract
Mutated human p53 may give rise to the formation of autoantibodies and may be a marker for a worse prognosis. We speculated that ascites or pleural effusions may enhance the formation of such autoantibodies in cancer patients and, therefore, we measured the presence of autoantibodies in the ascites or pleural effusion of 40 patients with advanced malignancies. As controls, p53 autoantibodies were measured in 15 patients with effusions who did not have a malignancy. Using a specific enzyme-linked immunosorbent assay, p53 autoantibodies could only be detected in the effusions of 5/40 patients (12.5%) with known malignancies. The formation of autoantibodies did not correlate with the presence or absence of tumor cells in the effusion. The effusions of the patients without tumor were all negative for p53 autoantibodies. Our study shows that malignant or reactive effusions do not stimulate the local or systemic production of autoantibodies against p53.
- Published
- 1996
- Full Text
- View/download PDF
44. [Expression of transforming growth factor beta-3 (TGF-beta-3) on reactive and malignant cells in ascites and pleural effusion].
- Author
-
Munker R, Darsow M, Stötzer O, Kremer JP, and Mezger J
- Subjects
- Adult, Aged, Ascitic Fluid pathology, Female, Humans, Male, Middle Aged, Neoplasms pathology, Pleural Effusion, Malignant pathology, Ascitic Fluid genetics, Cell Division genetics, Neoplasms genetics, Pleural Effusion, Malignant genetics, Transforming Growth Factor beta genetics, Tumor Cells, Cultured pathology
- Abstract
Patients and Method: The expression of TGF-beta-3 was examined in 64 patients with reactive and malignant effusion by immunocytochemistry., Result: In about half of the patients with malignant effusions (especially breast cancer, gastric cancer, and carcinomas of unknown primary) TGF-beta positive tumor cells could be detected. We could show here for the first time that reactive mesothelial cells could also express TGF-beta. Lymphatic cells were negative in all cases. TGF-beta-3 bioactivity could also be detected in the effusions studied. In our group of patients with far advanced cancer, the expression of TGF-beta had no clear-cut clinical or prognostic correlate. However, the expression of TGF-beta on tumor cells should be interpreted as a marker of tumor progression, taking into account the fibrogenic, angiogenic and immunosuppressive properties of TGF-beta., Conclusion: Further research is necessary to answer the question if the 3 isoforms of TGF-beta are coordinately expressed and to elucidate the involvement of this cytokine in tumor progression and metastasis.
- Published
- 1994
45. [Polyostotic fibrous dysplasia of the spinal column and ribs].
- Author
-
Walther EU, Grunewald R, Stötzer OJ, and Jehn U
- Subjects
- Diagnosis, Differential, Diagnostic Errors, Fibrous Dysplasia, Polyostotic surgery, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Radionuclide Imaging, Spinal Diseases surgery, Spine diagnostic imaging, Spine pathology, Tomography, X-Ray Computed, Fibrous Dysplasia, Polyostotic diagnosis, Ribs diagnostic imaging, Ribs pathology, Spinal Diseases diagnosis
- Abstract
The chest radiograph of a 56-year-old man with pain over the entire region of back, chest and vertebral column revealed chunky swelling over the 7th right rib. Other radiographs and magnetic resonance imaging further showed an infiltrative process in the 12th thoracic and the 2nd as well as 4th lumbar vertebrae. Skeletal scintigraphy was highly suggestive of bone metastases. Results of laboratory tests were within normal limits. Partial rib resection was performed after failure to find the site of a primary tumour. The diagnosis of polyostotic fibrous dysplasia was made histologically. There was no evidence of malignancy and a rare additional endocrinopathy (McCune-Albright syndrome) was excluded.
- Published
- 1993
- Full Text
- View/download PDF
46. Identification of carcinoma cells in ascitic and pleural fluid. Comparison of four panepithelial antigens with carcinoembryonic antigen.
- Author
-
Mezger J, Stötzer O, Schilli G, Bauer S, and Wilmanns W
- Subjects
- Ascitic Fluid pathology, Carcinoembryonic Antigen analysis, Glycoproteins analysis, Humans, Immunoenzyme Techniques, Membrane Glycoproteins analysis, Mucin-1, Neoplasms pathology, Pleural Effusion pathology, Pleural Effusion, Malignant immunology, Pleural Effusion, Malignant pathology, Antigens, Neoplasm analysis, Ascitic Fluid immunology, Biomarkers, Tumor immunology, Neoplasms immunology, Pleural Effusion immunology
- Abstract
The cell membrane antigens epithelial membrane antigen (EMA), epithelial glycoprotein 34, (egp34), BW-495 and tumor-associated antigen 72 (TAG-72) are present in most benign and malignant epithelial cells and can be demonstrated with the help of monoclonal antibodies. In a study on the identification of carcinoma cells in samples of ascitic and pleural fluid involving 170 patients, we compared the value of immunocytochemical labeling of these antigens with that of immunocytochemical demonstration of carcinoembryonic antigen (CEA). Antibodies to EMA and egp34 occasionally also reacted with reactively proliferating mesothelial cells in benign conditions and thus appear to be inappropriate for diagnostic use. Cells positive for BW-495, TAG-72 and CEA, however, have never been found in benign conditions; the specificity of these antigens thus permits their use in diagnosis. Antigen-expressing cells were found in 85% (BW-495), 62% (TAG-72) and 60% (CEA) of cytologically positive samples from carcinoma patients. Similarly, positive reactions for BW-495, TAG-72 and CEA were observed in, respectively, 36%, 29% and 34% of cytologically negative or suspicious samples. BW-495 thus appears to be a suitable marker for the demonstration of carcinoma cells in samples of pleural and ascitic fluid and to have a higher degree of sensitivity than does either TAG-72 or CEA.
- Published
- 1992
47. [Can carcinoma cells in ascitic and pleural effusions be reliably identified by immunocytochemical detection of "panepithelial antigens" EMA, egp34, BW-495 and TAG-72?].
- Author
-
Mezger J, Stötzer O, Schilli G, Bauer S, and Wilmanns W
- Subjects
- Diagnosis, Differential, Humans, Immunoenzyme Techniques, Mucin-1, Peritoneal Neoplasms secondary, Pleural Neoplasms secondary, Antigens, Neoplasm analysis, Ascites pathology, Biomarkers, Tumor analysis, Glycoproteins analysis, Membrane Glycoproteins analysis, Peritoneal Neoplasms pathology, Pleural Effusion, Malignant pathology, Pleural Neoplasms pathology
- Published
- 1991
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.